FibroGen completes pamrevlumab arm in Precision Promise Phase 2/3 trial

FibroGen announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s, PanCAN, Precision Promise Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma, mPDAC. Topline data from this registration study is anticipated in the second quarter of 2024. Pamrevlumab, in Stage 1 of the trial, achieved a protocol pre-specified greater than or equal to 35% predictive probability of success for the primary endpoint of overall survival at the completion of the trial, and thus graduated to the second and final Stage of the trial in the third quarter of 2022. Pamrevlumab is the first experimental arm to meet its required threshold for graduation to Stage 2 in the adaptive platform trial. The pamrevlumab arm of the study completed Stage 2 of the trial in January 2024. “We are excited to announce the achievement of this significant milestone in Precision Promise. The graduation and completion of the pamrevlumab arm of this study brings a potential new therapy one step closer for patients with metastatic pancreatic cancer, an underserved population with limited treatment options,” said Thane Wettig, Chief Executive Officer, FibroGen. “We look forward to continuing to work with PanCAN in sharing the topline data in the coming months.”